Antibody–drug conjugates (ADCs) are among the fastest growing therapeutic modalities in modern cancer drug research and development. These medicines combine the tumour-targeting properties of ...

China is racing ahead of global peers in the R&D of antibody-drug conjugate (ADC) drugs, we assess the market potential. Antibody-drug conjugates (ADC) are a class of biological drugs for the ...

Antibody–drug conjugates (ADCs) deliver potent anti-cancer drugs directly to tumor cells by taking advantage of the ability of antibodies to recognize cancer cell receptors. This targeted ...

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Assessing the pharmacokinetics (PK) of antibody-drug conjugates (ADCs) in both preclinical and clinical settings is crucial for their development. Biotransformation processes can lead to the ...

While they have been around for some years, ADCs – which pair antibodies with a drug payload designed to boost their efficacy – are gathering momentum in biopharma drug development as early ...

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...

Antibody-drug conjugates (ADCs) can be described as highly targeted biopharmaceutical drugs that integrate monoclonal antibodies specific to surface antigens and highly potent anti-cancer agents ...

a potential best-in-class next-generation antibody-drug conjugate (ADC), at the EORTC-NCI-AACR (ENA) Symposium 2024 in Barcelona, Spain, as an oral presentation during the plenary session.

A first-in-class antibody-drug conjugate (ADC), Elahere, was added to AbbVie’s portfolio earlier this year in February following the acquisition of ImmunoGen for $10.1 billion.

Antibody-drug conjugates or ADCs like Dato-DXd are being considered a disruptive innovation in the pharmaceutical industry as ...